Cuminaldehyde ameliorates hyperglycemia in diabetic mice

Front Biosci (Elite Ed). 2022 Sep 21;14(4):24. doi: 10.31083/j.fbe1404024.

Abstract

Background: Animal-fats are rich in long-chain saturated fatty-acids, well known to induct diabetic distress among ingested insulin-insensitive individuals. In the current-study, bovine-fat was fed to selective mice breeds highly sensitized to heavy dietary lipid load.

Methods: The later high fat diet (HFD) group indeed undergone diabetic-onset within weeks with a drastically altered feed-behavior pattern. It consumed more food, gained body mass, elevated homeostatic model assessment value and extensively glycosylated Hb transporters.

Results: However, the hypothetical test drug (Cuminaldehyde or CA) with known therapeutic-potential worked-well to balance food efficiency-ratio and Hb- counts closer to control. The fat-soluble phytochemical mono-terpenoid (CA) promoted constitutive mono-hexose (glucose) consuming catabolic-cycles via mono-glycoprotein (insulin) signal-transduction. It resolved diabetogenic-upsurge of gluconeogenic-enzymes, reduced non-sugar (amino/fatty acids) utilization by restricting transamination/dephosphorylation and restored liver-glycogen reserves near to normal-group effectively at 10 mg/kg b.w dose.

Conclusions: Hence, the nutraceutical-potential (anti-diabetes/transaminitis ability) of administered exogenous redox-active agent CA can be entertained for evoking therapeutic-heath in diabetic human-community.

Keywords: Cuminaldehyde; Glycosylated hemoglobin; High-fat diet; Insulin resistance; Oral glucose tolerance test.

MeSH terms

  • Animals
  • Cattle
  • Diabetes Mellitus, Experimental* / drug therapy
  • Dietary Fats / pharmacology
  • Humans
  • Hyperglycemia*
  • Insulin / pharmacology
  • Insulin Resistance* / physiology
  • Liver
  • Mice
  • Mice, Inbred C57BL

Substances

  • cuminaldehyde
  • Insulin
  • Dietary Fats